The NICE press team issues press releases on all published Clinical Guidelines, Technology Appraisals, and Public Health guidance, as well as for consultations on draft guidance and other news from NICE. Press releases are usually issued under embargo on the day before they are published on the website. If you are a journalist and would like to be added to our mailing list, please send an email to pressoffice@nice.org.uk or call the press team on 0845 003 7782.
|
|
NICE publishes final draft recommendations for a new treatment for enlarged spleen in adults with a rare blood cancer
NICE has published final draft guidance not recommending ruxolitinib (Jakavi, Novartis), for the treatment of disease-related splenomegaly (enlarged spleen) or its symptoms in adults with primary myelofibrosis, or post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.
April 26, 2013
|
|
NICE gives green light to treatment for asthma in final guidance
NICE has recommended omalizumab (Xolair, Novartis Pharmaceuticals UK) as an option for treating severe, persistent allergic asthma in adults, adolescents and children in final guidance.
April 24, 2013
|
|
NICE recommends drug for idiopathic pulmonary fibrosis in final guidance
The National Institute for Health and Care Excellence (NICE) has published final guidance for the NHS, which recommends pirfenidone (marketed as Esbriet and manufactured by InterMune) for certain people who have the chronic lung condition, idiopathic pulmonary fibrosis.
April 24, 2013
|
|
NICE recommends treatments for fractured bones in the spine
NICE, the health and social care guidance body, has published final guidance recommending two treatments for fractured bones in the spine (vertebrae) caused by osteoporosis.
April 24, 2013
|
|
NICE recommends wider use of abatacept for treating rheumatoid arthritis
NICE, the health and social care guidance body, has recommended abatacept (Orencia) for rheumatoid arthritis after conventional drug treatments (disease-modifying anti-rheumatic drugs, DMARDs) have failed.
April 24, 2013
|
|
New draft guidance on helping children and young people manage their weight
The National Institute for Health and Care Excellence (NICE) has begun a consultation on draft guidance on the services available to help children and young people to achieve and maintain a healthy weight.
April 22, 2013
|
|
NICE issues latest draft guidance on bevacizumab for recurrent advanced ovarian cancer
The cancer treatment bevacizumab (Avastin, Roche) is not recommended as an NHS treatment for a type of recurrent, advanced ovarian cancer*, according to the latest draft guidance published by the National Institute for Health and Care Excellence (NICE)
April 19, 2013
|
|
Draft guidance from NICE recommends new treatment option for potentially fatal blood clotting disease
NICE has issued final draft guidance recommending rivaroxaban (Xarelto, Bayer Healthcare) as a clinically and cost-effective option for treating pulmonary embolism (PE) and preventing recurrent deep vein thrombosis (DVT) and PE after acute PE in adults.
April 19, 2013
|
|
Draft guidance from NICE says yes to ranibizumab for common eye condition
The National Institute for Health and Care Excellence (NICE), the independent body responsible for driving quality improvement and excellence in the health and social care system, has issued final draft guidance recommending ranibizumab (Lucentis, Novartis) as a treatment for sight problems caused by macular oedema, which affects someone?s ability to see detail and colour.
April 11, 2013
|
|
NICE seeks views on draft guidance for non-Hodgkin's lymphoma treatment
A treatment for a type of non-Hodgkin?s lymphoma is not recommended for NHS use in draft NICE guidance. An independent committee concluded there was insufficient evidence to show that pixantrone (Pixuvri, Cell Therapeutics) is more effective than current NHS treatments and it does not represent good value for money.
April 11, 2013
|
This page was last updated: 26 April 2013